Skip to main content
Premium Trial:

Request an Annual Quote

Rajen Dalal, John Walker, and Keith Olson

Premium

Guava Technologies president and CEO Rajen Dalal has resigned, the Hayward, Calif.-based company said last week. John Walker, the chairman of Guava’s board of directors, has taken over the company as interim CEO.

In addition to his involvement with Guava, Walker is an investment advisor to MDS Capital and a vice chairman for biotechnology company Renovis. He is also a director of Discovery Partners International, Geron, and KAI Pharmaceuticals. In the past, Walker was CEO of KAI Pharmaceuticals, Bayhill Therapeutics, Centaur Pharmaceuticals, and Axys Pharmaceuticals, Guava said.

Keith Olson, Guava’s director of product commercialization, has also left the company, Inside Bioassays has learned. Olson has taken a position with Fremont, Calif.-based drug discovery firm DiscoverX, Guava said.

 

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.